A randomized controlled study of the effects of 17beta-estradiol- dydrogesterone on plasma homocysteine in postmenopausal women

Obstetrics and Gynecology

Volumn 91, Issue 3, 1998, Pages 432-436

  Mijatovic, Velja ^a   Kenemans, Peter ^a,b   Jakobs, Cornelis ^a   Marchien Van Baal, W ^a   Peters Muller, Edith R ^a   Van Der Mooren, Marius J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; HOMOCYSTEINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

DYDROGESTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOMOCYSTEINE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 0032030666     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00704-7     Document Type: Article

References (23)

1. 1. Pines A, Mijatovic V, van der Mooren MJ, Kenemans P. Hormone replacement therapy and cardioprotection: Basic concepts and clinical considerations. Eur J Obstet Gynecol Reprod Biol 1997;71:193-7.
2. 2. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
3. 3. Den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Weijermans PW, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.
4. 4. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-30.
5. 5. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullman D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268: 877-81.
6. 6 Brattström LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism 1985;35:1073-7.
7. 7. Wouters MGAJ, Moorrees MThEC, van der Mooren MJ, Blom HJ, Boers GHJ, Schellekens LA, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801-5.
8. 8. Van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733-6.
9. 9. Van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Homocysteine concentrations may decrease during postmenopausal hormone replacement therapy. Ir J Med Sci 1995;164 Suppl 15:21.
10. 10. Whitehead MI, Hillard T, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75:59S-76S.
11. 11. Crook D, Godsland IF, Stevenson JC. The cardiovascular risk profile of hormone replacement therapies containing dydrogesterone: A review. Eur Menopause J 1995;2 Suppl 4:23-30.
12. 12. Ubbink JB, Vermaak WHJ, Bissbort S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991;565:441-6.
13. 13. Thomas CMG, van den Berg RJ, Segers MFG, Bartelink ML, Thien T. Inaccurate measurements of 17β-oestradiol in serum of female volunteers after oral administration of milligram amounts of micronised 17β-oestradiol. Clin Chem 1993;39:2341-2.
14. 14. Anker G, Lønning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995;60:365-8.
15. 15. Van der Mooren MJ, Demacker PNM, Blom HJ, De Rijke YB, Rolland R. The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women. Fertil Steril 1997;67:67-73.
16. 16. Gelfand MM, Fugere P, Bissonnette F, Wiita B, Yang HM, Lorrain J, et al. Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: Effects on lipoproteins, glucose tolerance, endometrial histology, and bleeding. Menopause 1997;4:10-8.
17. 17. Kim MH, Kim E, Passen EL, Meyer J, Kang SS. Cortisol and estradiol: Non-genetic factors for hyperhomocyst(e)inemia. Metabolism 1997;46:247-9.
18. 18. Finkelstein J. Methionine metabolism in mammals. Effect of age, diet, and hormones on three enzymes of the pathway in rat tissues. Arch Biochem Biophys 1972;122:583-90.
19. 19. Blom HJ, Boers GHJ, Elzen JPAM, Van Roessel JJM, Trijbels JMF, Tangerman A. Difference between premenopausal women and young men in the transamination pathway of methionine catabolism and the protection against vascular disease. Eur J Clin Invest 1988;18:633-8.
20. 20. Rees MM, Rodgers GM. Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71:337-59.
21. 21. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res 1993;70:123-9.
22. 22. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
23. 23. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.